Navigation Links
Keraderm to Release $100 Phototherapy Treatment for Fungal Nail Infections
Date:9/17/2008

HAMPTON, Va., Sept. 17 /PRNewswire/ -- Keraderm, a leader in the development of phototherapy treatments for infections, plans to introduce a $100 phototherapy treatment for fungal nail infections (onychomycosis) in 2009 upon completion of their current pivotal trials and pending marketing clearance from the FDA.

"Our goal," states Keraderm CEO Bill Cumbie, "is to develop a safe and effective treatment for onychomycosis that can be accessed by a large number of people at a low cost. Many people cannot use current medications due to their high cost, significant side effects, and contraindications while taking other medications. Our pilot clinical trials have indicated the efficacy of the best oral medications with no significant side effects. We will establish the safety and efficacy of our treatment with our current pivotal clinical trials which will be submitted to the FDA for approval as the first phototherapy treatment for onychomycosis. The beauty of our treatment is that it can be delivered easily and inexpensively. We hope to introduce our treatment in 2009 at $100 for several treatments and continue to improve the technology so that eventually only one treatment in the $100 range will be necessary. We are also working to establish insurance reimbursement for our therapy which will further reduce cost to the consumer."

Keraderm is well on the way to being the first phototherapy treatment approved by the FDA for onychomycosis with its research published in the prestigious peer-reviewed British Journal of Dermatology and presented at the 2007 World Congress of Dermatology and the 2008 Annual Conference of the American Academy of Dermatology. Keraderm also has a growing portfolio of national and international patents that protect the key aspects of its proprietary platform technology to treat infections.

About Keraderm

Keraderm LLC is a medical device company with proprietary, patented, platform technology for a wide variety of infections. This technology has the potential to effectively treat infections without the serious side effects that many medications have and to effectively treat infections caused by drug resistant organisms such as MRSA. Keraderm has obtained patents on its key technologies to treat infections and has a number of additional patent applications pending on refinements of its technology. Published laboratory and clinical studies indicate that the technology has great potential to effectively and safely treat infections.

Forward-looking statements

Statements in this press release containing the words believe, may, expect, project and other similar expressions are forward looking statements that are not definite and have a number of risks and uncertainties. Representative factors that can cause actual results to differ from those projected include the following: regulatory clearance of products, market acceptance; financial constraints; government regulations; obtaining and enforcing intellectual property rights; attracting and retaining key employees; developing partnership opportunities; timing of commercial product launches; and other similar internal and external risks factors.

Media Contact:

Bill Cumbie

144 Research Drive

Hampton, VA 23666

(757) 344-8607

http://www.keraderm.com

bill@keraderm.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Keraderm LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
2. Tourtellotte Solutions Blazes Trail with New Release of Clinical Trial Supply Chain Simulator
3. CEL-SCI Corporation Releases Letter to Shareholders
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. AcroMetrix Releases New OptiQuant(R) HIV-1 Quantification Panel
6. ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients
7. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
8. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
9. Immunosyn Corporation Releases SF-1019 Study Results
10. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
11. Keppra XR(TM) Extended-Release Tablets Filed with the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
Breaking Medicine Technology:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
Breaking Medicine News(10 mins):